https://www.selleckchem.com/pr....oducts/wnt-agonist-1
asive biomarker to predict response to checkpoint inhibitors in NSCLC within the first month. Although the mitogen-activated protein kinases (MAPK) pathway is hyperactive in head and neck cancer (HNC), inhibition of MEK1/2 in HNC patients has not shown clinically meaningful activity. Therefore, we aimed to characterize the effect of MEK1/2 inhibition on the tumor microenvironment (TME) of MAPK-driven HNC, elucidate tumor-host interaction mechanisms facilitating immune escape on treatment, and apply rationale-based therapy combinat
Aimer
Commentaire
Partagez
